Naglazyme
Biological
BioMarin Pharmaceutical Inc.
Total Payments
$572,823
Transactions
299
Doctors
53
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2022 | $10,120 | 7 | 2 |
| 2021 | $237,777 | 13 | 1 |
| 2020 | $40,300 | 25 | 1 |
| 2019 | $97,354 | 35 | 11 |
| 2018 | $99,362 | 91 | 12 |
| 2017 | $87,910 | 128 | 40 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $497,564 | 161 | 86.9% |
| Travel and Lodging | $30,193 | 27 | 5.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $24,017 | 6 | 4.2% |
| Consulting Fee | $13,143 | 3 | 2.3% |
| Food and Beverage | $4,124 | 96 | 0.7% |
| Honoraria | $3,500 | 1 | 0.6% |
| Education | $282.00 | 5 | 0.0% |
Payments by Type
Research
$497,564
161 transactions
General
$75,258
138 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| MPS VI Clinical Surveillance Program CSP) | BioMarin Pharmaceutical Inc. | $272,808 | 0 |
| Study of Administration of Intravenous Naglazyme Following Allogeneic Transplantation for Maroteaux-Lamy Syndrome | BioMarin Pharmaceutical Inc. | $84,273 | 0 |
| MPS VI Clinical Surveillance Program CSP | BioMarin Pharmaceutical Inc. | $58,599 | 0 |
| Five Year Follow-up Study to ASB-008 - A Phase 4 Multi-Center, Multi-National, Open-Label Randomized, Two Dose Level Study of Naglazyme galsufase) in Infants with Maroteaux-Lamy Syndrome MPS VI). | BioMarin Pharmaceutical Inc. | $49,371 | 0 |
| A Five Year Follow-up Study to ASB-008 A Phase 4 Multi-Center, Multi-National, Open-Label Randomized, Two Dose Level Study of Naglazyme galsufase) in Infants with Maroteaux-Lamy Syndrome MPS VI) | BioMarin Pharmaceutical Inc. | $18,514 | 0 |
| MPS VI Clinical Surveillance Program (CSP) | BioMarin Pharmaceutical Inc. | $11,484 | 0 |
| PKU Demographics, Outcomes, and Safety Registry | BioMarin Pharmaceutical Inc. | $1,715 | 0 |
| MPS VI Clinical Surveillance Program CP | BioMarin Pharmaceutical Inc. | $800.00 | 0 |
Top Doctors Receiving Payments for Naglazyme
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Kansas City, MO | $497,564 | 161 |
| , MD | Pediatric Gastroenterology | Oakland, CA | $40,110 | 31 |
| , MD | Orthopaedic Surgery | Seattle, WA | $26,780 | 20 |
| , MD | Clinical Genetics (M.D.) | Chicago, IL | $3,819 | 8 |
| , M.D | Pediatric Orthopaedic Surgery | Uniondale, NY | $1,469 | 4 |
| , M.D | Clinical Genetics (M.D.) | Philadelphia, PA | $473.16 | 4 |
| , M.D | Clinical Biochemical Genetics | Fort Worth, TX | $260.21 | 5 |
| , MD | Medical Genetics, Ph.D. Medical Genetics | Valhalla, NY | $135.79 | 1 |
| , MD | Pediatrics | Sioux Falls, SD | $125.66 | 3 |
| , M.D | Student in an Organized Health Care Education/Training Program | Chicago, IL | $125.66 | 3 |
| , M.D., M.S | Clinical Genetics (M.D.) | New York, NY | $124.63 | 3 |
| , MD | Anesthesiology | Aurora, CO | $121.75 | 2 |
| , MD | Pediatrics | Long Beach, CA | $119.96 | 2 |
| , M.D.,PH.D | Clinical Genetics (M.D.) | Cleveland, OH | $100.00 | 2 |
| , MD | Clinical Genetics (M.D.) | Salt Lake City, UT | $98.48 | 1 |
| , MD | Clinical Biochemical Genetics | Albany, NY | $98.48 | 1 |
| , MD | Clinical Genetics (M.D.) | Washington, DC | $97.59 | 2 |
| , D.O | Emergency Medicine | Hamilton, AL | $72.58 | 1 |
| , MD | Clinical Biochemical Genetics | Dayton, OH | $70.00 | 1 |
| , MD | Clinical Genetics (M.D.) | Omaha, NE | $69.07 | 3 |
| , MD | Clinical Genetics (M.D.) | Omaha, NE | $69.07 | 3 |
| , M.D | Medical Biochemical Genetics | Akron, OH | $63.13 | 2 |
| , M.D | Clinical Biochemical Genetics | Cincinnati, OH | $59.56 | 2 |
| , MD | Clinical Genetics (M.D.) | Phoenix, AZ | $56.49 | 1 |
| , M.D | Medical Biochemical Genetics | San Diego, CA | $46.41 | 2 |
Ad
Manufacturing Companies
- BioMarin Pharmaceutical Inc. $572,823
Product Information
- Type Biological
- Total Payments $572,823
- Total Doctors 53
- Transactions 299
About Naglazyme
Naglazyme is a biological associated with $572,823 in payments to 53 healthcare providers, recorded across 299 transactions in the CMS Open Payments database. The primary manufacturer is BioMarin Pharmaceutical Inc..
Payment data is available from 2017 to 2022. In 2022, $10,120 was paid across 7 transactions to 2 doctors.
The most common payment nature for Naglazyme is "Unspecified" ($497,564, 86.9% of total).
Naglazyme is associated with 8 research studies, including "MPS VI Clinical Surveillance Program CSP)" ($272,808).